Burkitt lymphoma is a highly aggressive B-cell malignancy characterized by rapid proliferation and a narrow therapeutic window in which early recognition of disease progression is critical to prevent morbidity. While diagnosis is typically established through histopathology and imaging, evolving physiologic and radiographic changes may provide early indicators of aggressive disease behavior, particularly in the post treatment setting. We present a 26-year-old male patient with previously treated Epstein-Barr virus-positive Burkitt lymphoma who presented with acute lower back pain, urinary symptoms, and rapid clinical deterioration consistent with disease progression. Laboratory evaluation demonstrated normocytic anemia, markedly elevated lactate dehydrogenase, progressive leukocytosis, and hypoalbuminemia, consistent with a high tumor burden. Cross-sectional imaging revealed interval enlargement of a necrotic pelvic mass with associated hydronephrosis, while MRI demonstrated diffuse marrow infiltration. Fluorodeoxyglucose-Positron emission tomography/Computed tomography (FDG PET/CT) showed extensive hypermetabolic disease involving nodal and extranodal sites, consistent with systemic progression. Peripheral blood flow cytometry failed to identify a clonal B-cell population, a finding consistent with known limitations of circulating markers in Burkitt lymphoma, particularly following recent chemotherapy. This case highlights a physiologic pattern of oncologic emergency, defined by integrated laboratory abnormalities, imaging progression, and clinical decline as indicators of disease progression. Recognition of these features may facilitate timely therapeutic escalation despite inconclusive peripheral findings.
Bidgoli et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: